Top Markets
Coin of the day
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Rang in Aktien #29898
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Aktienkurs
$1.10
Zuletzt synchronisiert: 2023-06-07
Marktkapitalisierung
$19.12M
Veränderung (1 Tag)
-0.90%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Satsuma Pharmaceuticals, Inc. (STSA)

Kategorie

Kursverlauf für Satsuma Pharmaceuticals, Inc. (STSA)
Höchster Schlusskurs: $1.08 am 2023-06-01

Niedrigster Schlusskurs: $15.51 am 2019-09-01
Kursverlauf der Aktie von Satsuma Pharmaceuticals, Inc. von 2019 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 24.48%
2022 -81.02%
2021 -5.23%
2020 -69.52%
2019 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.89 35.09%
US
$996.61 51.72%
NL
$117.42 -19.34%
AU
$737.68 6.34%
CH
$1.07K -5.58%
KR